Chinese biotech inks ADC platform deal with ConjugateBio

CAR-T Digest - August 2020

25 Apr 2025: Chinese biotech inks ADC platform deal with ConjugateBio

Escugen has signed an exclusive option agreement with ConjugateBio to license its EZWi-Fit platform for next-generation antibody-drug conjugates (ADCs)
ConjugateBio gains an exclusive option for certain ADC targets, with global rights and over $100 million in potential milestone payments and royalties if exercised
The deal highlights growing international interest in Escugen’s proprietary linker-payload ADC platform
This agreement expands Escugen’s global presence in the increasingly competitive ADC technology landscape
The platform licensing strategy supports Escugen’s broader goal of establishing itself as a key player in differentiated ADC development